{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:00:02Z","timestamp":1772164802917,"version":"3.50.1"},"reference-count":53,"publisher":"American Association for Cancer Research (AACR)","issue":"10","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HHS | National Institutes of Health","award":["K12 HD050121"],"award-info":[{"award-number":["K12 HD050121"]}]},{"name":"HHS | NIH | National Cancer Institute","award":["CA208354"],"award-info":[{"award-number":["CA208354"]}]},{"name":"HHS | NIH | National Cancer Institute","award":["CA222963"],"award-info":[{"award-number":["CA222963"]}]},{"name":"HHS | NIH | National Cancer Institute","award":["CA250101"],"award-info":[{"award-number":["CA250101"]}]},{"name":"Big Ten Research Consortium"},{"DOI":"10.13039\/100018096","name":"GOG Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018096","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,28]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The objective of this study was to assess the efficacy and safety of pembrolizumab in combination with standard carboplatin\/paclitaxel in patients with advanced endometrial cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>This single-arm, open-label, multicenter phase II study enrolled patients with RECIST measurable advanced endometrial cancer. Patients could have received \u2264 1 prior platinum-based regimen and \u2264 one non-platinum chemotherapy. The primary endpoint was objective response rate (ORR). Planned sample size of 46 subjects provided 80% power to detect 15% ORR improvement compared with historical control rate of 50%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 46 patients were enrolled and 43 were evaluable for ORR. Median age was 66 (range: 43\u201386). Thirty-four (73.9%) patients had recurrent and 12 (26.1%) primary metastatic endometrial cancer. Patients received carboplatin AUC6, paclitaxel 175 mg\/m2, and pembrolizumab 200 mg i.v. every 3 weeks for up to six cycles. ORR was 74.4% (32\/43), higher than historic controls (P = 0.001). Median progression-free survival (PFS) was 10.6 months (95% confidence interval, 8.3\u201313.9 months). The most common grade 1\u20132 treatment-related adverse event (TRAE) included anemia (56.5%), alopecia (47.8%), fatigue (47.8%), and neuropathy (13%), while the most common grade 3\u20134 TRAEs were lymphopenia, leukopenia, and anemia (19.6% each). High-dimensional spectral flow cytometry (CyTEK) identified enrichment in peripheral CD8+ and CD4+ T-cell populations at baseline in responders. The CD8+ T-cell compartment in responders exhibited greater expression levels of PD-1 and PD-L1 and higher abundance of effector memory CD8+ cells compared with nonresponders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Addition of pembrolizumab to carboplatin and paclitaxel for advanced endometrial cancer was tolerated and improved ORR compared with historical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The results of the study support that the combination of pembrolizumab with carboplatin and paclitaxel is well tolerated and active in patients with advanced endometrial cancer. The duration of response and the PFS were significantly longer in patients with mismatch repair deficient\/microsatellite instability-high compared with mismatch repair proficient\/microsatellite stable tumors. Responders to treatment tend to have enriched CD8+ T-cell and CD4+ T-cell populations among peripheral blood mononuclear cells at baseline.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-22-0147","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T21:10:15Z","timestamp":1661375415000},"page":"1293-1303","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium"],"prefix":"10.1158","volume":"2","author":[{"given":"Emma L.","family":"Barber","sequence":"first","affiliation":[{"name":"1Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, Illinois."},{"name":"2Robert H Lurie Comprehensive Cancer center, Chicago, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqi","family":"Chen","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Northwestern University, Chicago, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario Javier","family":"Pineda","sequence":"additional","affiliation":[{"name":"4Ironwood Cancer and Research Centers, Gilbert, Arizona."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon E.","family":"Robertson","sequence":"additional","affiliation":[{"name":"5Department of Obstetrics and Gynecology, Indiana University, Indianapolis, Indiana."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7612-0266","authenticated-orcid":true,"given":"Emily K.","family":"Hill","sequence":"additional","affiliation":[{"name":"6Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City, Iowa."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deanna","family":"Teoh","sequence":"additional","affiliation":[{"name":"7Department of Obstetrics and Gynecology, University of Minnesota, Minneapolis, Minnesota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6322-5376","authenticated-orcid":true,"given":"Jeanne","family":"Schilder","sequence":"additional","affiliation":[{"name":"5Department of Obstetrics and Gynecology, Indiana University, Indianapolis, Indiana."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7971-1387","authenticated-orcid":true,"given":"Kaitlyn L.","family":"O'Shea","sequence":"additional","affiliation":[{"name":"8Department of Preventive Medicine, Northwestern University, Chicago, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masha","family":"Kocherginsky","sequence":"additional","affiliation":[{"name":"2Robert H Lurie Comprehensive Cancer center, Chicago, Illinois."},{"name":"8Department of Preventive Medicine, Northwestern University, Chicago, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[{"name":"2Robert H Lurie Comprehensive Cancer center, Chicago, Illinois."},{"name":"3Department of Medicine, Northwestern University, Chicago, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2169-5035","authenticated-orcid":true,"given":"Daniela","family":"Matei","sequence":"additional","affiliation":[{"name":"1Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, Illinois."},{"name":"2Robert H Lurie Comprehensive Cancer center, Chicago, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"2023032313492498700_","unstructured":"American Cancer Society Key Statistics for Endometrial Cancer. Available from: https:\/\/www.cancer.org\/cancer\/endometrial-cancer\/about\/key-statistics.html."},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1089\/jwh.2018.6956","article-title":"Increased incidence of endometrial cancer following the women's health initiative: an assessment of risk factors","volume":"28","author":"Constantine","year":"2019","journal-title":"J Womens Health"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.15585\/mmwr.mm6748a1","article-title":"Uterine cancer incidence and mortality - United States, 1999\u20132016","volume":"67","author":"Henley","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023032313492498700_","unstructured":"SEER Cancer Stat Facts: uterine cancer. NCI, Bethesda, MD. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/corp.html."},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology\/GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2004.07.184","article-title":"Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study","volume":"22","author":"Fleming","year":"2004","journal-title":"J Clin Oncol"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J Clin Oncol"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","article-title":"The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma","volume":"37","author":"Mahoney","year":"2015","journal-title":"Clin Ther"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2023032313492498700_","unstructured":"FDA grants accelerated approval tp pembrolizumab for first tissue\/site agnostic indication. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication."},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"5939","DOI":"10.1158\/1078-0432.CCR-18-0412","article-title":"Clinical utility of prospective molecular characterization in advanced endometrial cancer","volume":"24","author":"Soumerai","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.2017.72.5952","article-title":"Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J Clin Oncol"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Makker","year":"2019","journal-title":"Lancet Oncol"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrc.2017.17","article-title":"Prospects for combining targeted and conventional cancer therapy with immunotherapy","volume":"17","author":"Gotwals","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1038\/onc.2016.104","article-title":"Damage-associated molecular patterns in cancer: a double-edged sword","volume":"35","author":"Hernandez","year":"2016","journal-title":"Oncogene"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/s12885-020-06964-5","article-title":"Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells","volume":"20","author":"Solari","year":"2020","journal-title":"BMC Cancer"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","article-title":"Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Shu","year":"2020","journal-title":"Lancet Oncol"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J Clin Oncol"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1470-2045(21)00303-X","article-title":"Immunotherapy in ovarian cancer: we are not there yet","volume":"22","author":"Barber","year":"2021","journal-title":"Lancet Oncol"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"iv369","DOI":"10.1093\/annonc\/mdu342.23","article-title":"1070P - Adaptation of the immune related response criteria: irRECIST","volume":"25","author":"Bohnsack","year":"2014","journal-title":"Ann Oncol"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-13-0895","article-title":"Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements","volume":"19","author":"Nishino","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nbt.2594","article-title":"viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia","volume":"31","author":"Amir el","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/cyto.a.22625","article-title":"FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data","volume":"87","author":"Van Gassen","year":"2015","journal-title":"Cytometry A"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"5116","DOI":"10.1073\/pnas.091062498","article-title":"Significance analysis of microarrays applied to the ionizing radiation response","volume":"98","author":"Tusher","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ygyno.2013.09.021","article-title":"Applicability of the concept of \u201cplatinum sensitivity\u201d to recurrent endometrial cancer: the SGSG-012\/GOTIC-004\/Intergroup study","volume":"131","author":"Nagao","year":"2013","journal-title":"Gynecol Oncol"},{"key":"2023032313492498700_","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; 2020. Available from: https:\/\/www.R-project.org\/."},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (Stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): updated overall survival analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2019.04.044","article-title":"Preliminary safety, efficacy, and pharmacokinetic\/pharmacodynamic characterization from GARNET, a phase I\/II clinical trial of the anti\u2013PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-h and MSS endometrial cancer","volume":"154","author":"Oaknin","year":"2019","journal-title":"Gynecol Oncol"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1200\/JCO.19.01021","article-title":"Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent\/persistent endometrial cancer","volume":"37","author":"Konstantinopoulos","year":"2019","journal-title":"J Clin Oncol"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/JCO.2019.37.15_suppl.5501","article-title":"Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: the phase II PHAEDRA trial (ANZGOG1601)","volume":"37","author":"Antill","year":"2019","journal-title":"J Clin Oncol"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ygyno.2018.02.013","article-title":"Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer","volume":"149","author":"Kim","year":"2018","journal-title":"Gynecol Oncol"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-021-00301-z","article-title":"Immunotherapy in endometrial cancer: rationale, practice and perspectives","volume":"9","author":"Cao","year":"2021","journal-title":"Biomark Res"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3322\/caac.21561","article-title":"Current recommendations and recent progress in endometrial cancer","volume":"69","author":"Brooks","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"103040","DOI":"10.1016\/j.ebiom.2020.103040","article-title":"Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: translational evidence from two clinical trials","volume":"62","author":"Mankor","year":"2020","journal-title":"EBioMedicine"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/Anti-CTLA-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/2326-6066.CIR-19-0574","article-title":"CD4(+) T-cell immunity in the peripheral blood correlates with response to anti-PD-1 therapy","volume":"8","author":"Kagamu","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1073\/pnas.1705327114","article-title":"Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients","volume":"114","author":"Kamphorst","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s40425-019-0608-y","article-title":"CD45RA(+)CCR7(-) CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab","volume":"7","author":"Kunert","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.lungcan.2018.11.038","article-title":"The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC","volume":"127","author":"Mazzaschi","year":"2019","journal-title":"Lung Cancer"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.1158\/0008-5472.CAN-16-3167","article-title":"PD-1 status in CD8(+) T cells associates with survival and anti-PD-1 therapeutic outcomes in head and neck cancer","volume":"77","author":"Kansy","year":"2017","journal-title":"Cancer Res"},{"key":"2023032313492498700_","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-22-0147\/3199742\/crc-22-0147.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/10\/1293\/3284838\/crc-22-0147.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/10\/1293\/3284838\/crc-22-0147.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T23:45:41Z","timestamp":1700955941000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/2\/10\/1293\/710080\/Clinical-and-Biological-Activity-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,28]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0147","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.6550851","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6550851.v1","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.22545096.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545096","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]}}}